1. Home
  2. CERO vs APVO Comparison

CERO vs APVO Comparison

Compare CERO & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CERO
  • APVO
  • Stock Information
  • Founded
  • CERO 2017
  • APVO 2016
  • Country
  • CERO United States
  • APVO United States
  • Employees
  • CERO N/A
  • APVO N/A
  • Industry
  • CERO
  • APVO Biotechnology: Pharmaceutical Preparations
  • Sector
  • CERO
  • APVO Health Care
  • Exchange
  • CERO Nasdaq
  • APVO Nasdaq
  • Market Cap
  • CERO 8.4M
  • APVO 5.4M
  • IPO Year
  • CERO N/A
  • APVO N/A
  • Fundamental
  • Price
  • CERO $1.80
  • APVO $3.64
  • Analyst Decision
  • CERO
  • APVO Strong Buy
  • Analyst Count
  • CERO 0
  • APVO 1
  • Target Price
  • CERO N/A
  • APVO $296.00
  • AVG Volume (30 Days)
  • CERO 742.5K
  • APVO 40.3K
  • Earning Date
  • CERO 02-24-2025
  • APVO 03-04-2025
  • Dividend Yield
  • CERO N/A
  • APVO N/A
  • EPS Growth
  • CERO N/A
  • APVO N/A
  • EPS
  • CERO N/A
  • APVO N/A
  • Revenue
  • CERO N/A
  • APVO N/A
  • Revenue This Year
  • CERO N/A
  • APVO N/A
  • Revenue Next Year
  • CERO N/A
  • APVO N/A
  • P/E Ratio
  • CERO N/A
  • APVO N/A
  • Revenue Growth
  • CERO N/A
  • APVO N/A
  • 52 Week Low
  • CERO $1.70
  • APVO $3.52
  • 52 Week High
  • CERO $1,238.00
  • APVO $399.60
  • Technical
  • Relative Strength Index (RSI)
  • CERO 32.70
  • APVO 32.23
  • Support Level
  • CERO $1.70
  • APVO $3.77
  • Resistance Level
  • CERO $2.22
  • APVO $4.47
  • Average True Range (ATR)
  • CERO 0.31
  • APVO 0.28
  • MACD
  • CERO 0.26
  • APVO 0.01
  • Stochastic Oscillator
  • CERO 6.76
  • APVO 10.26

About CERO CERo Therapeutics Holdings Inc. Common Stock

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

About APVO Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Share on Social Networks: